[go: up one dir, main page]

FI974368L - Kasvuhormonin vapautumista edistäviä dipeptidejä - Google Patents

Kasvuhormonin vapautumista edistäviä dipeptidejä Download PDF

Info

Publication number
FI974368L
FI974368L FI974368A FI974368A FI974368L FI 974368 L FI974368 L FI 974368L FI 974368 A FI974368 A FI 974368A FI 974368 A FI974368 A FI 974368A FI 974368 L FI974368 L FI 974368L
Authority
FI
Finland
Prior art keywords
dipeptides
promote
release
growth hormone
hormone
Prior art date
Application number
FI974368A
Other languages
English (en)
Swedish (sv)
Other versions
FI974368A0 (fi
FI974368A7 (fi
Inventor
Philip A Carpino
Paul A Dasilva Jardine
Bruce A Lefker
John A Ragan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI974368A0 publication Critical patent/FI974368A0/fi
Publication of FI974368L publication Critical patent/FI974368L/fi
Publication of FI974368A7 publication Critical patent/FI974368A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
FI974368A 1995-05-29 1995-05-29 Kasvuhormonin vapautumista edistäviä dipeptidejä FI974368A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000410 WO1996038471A1 (en) 1995-05-29 1995-05-29 Dipeptides which promote release of growth hormone

Publications (3)

Publication Number Publication Date
FI974368A0 FI974368A0 (fi) 1997-11-28
FI974368L true FI974368L (fi) 1997-11-28
FI974368A7 FI974368A7 (fi) 1997-11-28

Family

ID=11004334

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974368A FI974368A7 (fi) 1995-05-29 1995-05-29 Kasvuhormonin vapautumista edistäviä dipeptidejä

Country Status (15)

Country Link
US (1) US5936089A (fi)
EP (1) EP0828754B1 (fi)
JP (1) JP3133073B2 (fi)
KR (1) KR960041192A (fi)
CN (1) CN1143647A (fi)
AT (1) ATE288444T1 (fi)
AU (1) AU5455496A (fi)
CA (1) CA2220055C (fi)
DE (1) DE69533991T2 (fi)
ES (1) ES2235171T3 (fi)
FI (1) FI974368A7 (fi)
IL (1) IL118330A0 (fi)
MX (1) MX9709278A (fi)
NO (1) NO962162L (fi)
WO (1) WO1996038471A1 (fi)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612276D0 (en) * 1996-06-12 1996-08-14 Merck & Co Inc 4-Spiroindoline piperidines promote release of growth hormone
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6240161B1 (en) * 1997-09-25 2001-05-29 Siemens Medical Systems, Inc. Multi-leaf collimator constrained optimization of intensity modulated treatments
BR9906975A (pt) 1998-01-16 2000-10-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ES2331102T3 (es) * 1998-05-11 2009-12-21 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
DE19859684A1 (de) * 1998-12-23 2000-06-29 Bayer Ag Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole
IL142816A0 (en) * 1998-12-24 2002-03-10 Du Pont Pharm Co SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US20020016298A1 (en) * 1999-09-01 2002-02-07 Hay Bruce A. Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6960576B2 (en) * 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
CA2386517A1 (en) * 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
WO2001027108A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
EP1268433A1 (en) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta-protein production
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
US6632812B2 (en) * 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
WO2001087834A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2001261728A1 (en) * 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
AU2001277727A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
WO2002014277A1 (en) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
WO2002079146A2 (en) * 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
ES2340147T3 (es) * 2001-04-12 2010-05-31 Pharmacopeia, Llc Piperidinas de arilo y biarilo usadas como antagonistas de mch.
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
DE50204789D1 (de) * 2001-05-10 2005-12-08 Solvay Pharm Gmbh Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
JP2005504043A (ja) 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7026335B2 (en) * 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
US20040010010A1 (en) * 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
JP4617449B2 (ja) 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
AU2003268493A1 (en) 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
US7132539B2 (en) * 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
EP1682537B1 (en) * 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
TWI341835B (en) * 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
RU2007129779A (ru) * 2005-01-06 2009-02-20 Астразенека Аб (Se) Новые соединения пиридина
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2012131090A1 (en) 2011-03-31 2012-10-04 Galderma Research & Development Method for treatment of xeroderma pigmentosum
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN104910254B (zh) * 2015-06-10 2018-05-01 华南农业大学 二肽Pro-Asp在促进动物肝细胞分泌IGF-1方面的应用
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3448520A4 (en) * 2016-04-29 2020-07-29 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
ES2927901T3 (es) * 2017-12-27 2022-11-11 Flamma Spa Derivados peptídicos y actividad terapéutica de los mismos
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPS5566375A (en) * 1978-08-17 1980-05-19 Hochiki Co Bubble fire extinguishing chemical for hydrophile inflammable liquid
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5317017A (en) * 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
AU676525B2 (en) * 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
HUT72076A (en) * 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
AU8083694A (en) * 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
WO1995013069A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone

Also Published As

Publication number Publication date
CN1143647A (zh) 1997-02-26
NO962162L (no) 1996-12-02
NO962162D0 (no) 1996-05-28
EP0828754A1 (en) 1998-03-18
EP0828754B1 (en) 2005-02-02
DE69533991T2 (de) 2006-04-13
ATE288444T1 (de) 2005-02-15
FI974368A0 (fi) 1997-11-28
WO1996038471A1 (en) 1996-12-05
DE69533991D1 (de) 2005-03-10
CA2220055C (en) 2001-04-24
JPH10510511A (ja) 1998-10-13
CA2220055A1 (en) 1996-12-05
AU5455496A (en) 1996-12-12
IL118330A0 (en) 1996-09-12
KR960041192A (ko) 1996-12-19
ES2235171T3 (es) 2005-07-01
FI974368A7 (fi) 1997-11-28
US5936089A (en) 1999-08-10
MX9709278A (es) 1998-03-31
JP3133073B2 (ja) 2001-02-05

Similar Documents

Publication Publication Date Title
FI974368L (fi) Kasvuhormonin vapautumista edistäviä dipeptidejä
DE69637063D1 (de) Oral verfügbare wachstumshormon-sekretagoge
DE69604860D1 (de) Orthopädisches Befestigungsmittel
DE69602931D1 (de) Befestiger
DE59509539D1 (de) Zwischenwirbel-implantat
FR2729291B1 (fr) Implant rachidien
EP0785784A4 (en) 4-heterocyclic piperidines promote release of growth hormone
NO962704D0 (no) Ankersystem
DK0724826T3 (da) Urtepotte
FI973116A0 (fi) Upokas
DE69611885D1 (de) Verbindungselement
FI973107A7 (fi) Hallitusti vapautuvat vesiympäristön ravintoaineet
FI972968L (fi) Menetelmiä kasvuhormonivaikutusten estämiseksi
IS4721A (is) Margbreytileg form af vaxtarhormóna seytisörvara (secretagogue)
KR960029215U (ko) 스트롱 앵커
KR960034960U (ko) 앵커너트
KR970042259U (ko) 체결구
DK0770046T3 (da) Gødningsmidler med kontrolleret frigivelse
KR970037352U (ko) 승합차량의 루프 사이드
KR970041866U (ko) 체결용 팻치
KR960030093U (ko) 밤 박피기
KR970015955U (ko) 장신구용 체결구
LV10611A (lv) Benzosaistitie laktami kas sekme augsanas hormona atbrivosanu
KR970042221U (ko) 탈장착이 용이한 파스너
KR970042156U (ko) 패스너

Legal Events

Date Code Title Description
MA Patent expired